Pfizer (PFE 1.00%) failed pursuit of AstraZeneca has dominated the news all month, but its filing for accelerated approval of palbociclib is nearly as important. This breast cancer drug, with peak sales estimates over $5 billion, could get an early date with the FDA. Pfizer will file for accelerated approval based on strong phase 2 data.
In this episode of The Motley Fool's health-care show Market Checkup, analysts David Williamson and Michael Douglass discuss the excitement around palbo, its importance to Pfizer, and a hidden stock that will get an 8% royalty on the drugs potentially massive sales.
